Gene Therapy for Heart Disease Wins Fast-Track Status – P&T Community
|
Gene Therapy for Heart Disease Wins Fast-Track Status
P&T Community The FDA has granted a fast-track designation for a phase 3 study of Generx (Ad5FGF-4, Angionetics Inc.) cardiovascular angiogenic gene therapy as a one-time treatment for improving exercise tolerance in patients with angina that is refractory to … |
